Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical

New York – March 17, 2025 – Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash. Under the terms of the agreement, Taiho Pharmaceutical will pay Araris $400 million upfront, with the potential for additional milestone payments of up to $740 million. The acquisition is expected to be completed in the first half of 2025 and follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023.

Lawyers Bill Roegge, Kenneth Krisko, Simon Amies, Rita Sobral and Stephanie Palmer led the Cooley team advising Araris.

A Cooley team including Kenneth Krisko, Frances Stocks Allen, Stephanie Palmer and Alexandra Paterson advised Araris on prior strategic collaboration matters, including a recent collaboration with a global pharmaceutical company. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.